Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "2022"

1412 News Found

GMM Pfaudler posts Q3 FY24 consolidated PAT at Rs. 31.72 Cr
News | February 03, 2024

GMM Pfaudler posts Q3 FY24 consolidated PAT at Rs. 31.72 Cr

GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023


Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr
News | February 02, 2024

Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr

Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023


Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr
News | February 02, 2024

Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr

Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023


Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr
News | February 02, 2024

Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr

Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023


Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr
News | February 02, 2024

Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr

Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023


Zydus Lifesciences launches Rexigo
News | February 01, 2024

Zydus Lifesciences launches Rexigo

This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India


Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr
News | February 01, 2024

Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr

Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023


Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr
News | January 28, 2024

Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr

Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023


Astec LifeSciences posts Q3 FY24 consolidated loss at Rs. 24.33 Cr
News | January 26, 2024

Astec LifeSciences posts Q3 FY24 consolidated loss at Rs. 24.33 Cr

Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023


Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr
News | January 25, 2024

Laurus Labs posts Q3 FY24 consolidated PAT at Rs. 23.14 Cr

Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023